Drugs

, Volume 61, Issue 14, pp 2035–2063

The Use of Silymarin in the Treatment of Liver Diseases

  • Reinhard Saller
  • Remy Meier
  • Reto Brignoli
Review Article

Abstract

The high prevalence of liver diseases such as chronic hepatitis and cirrhosis underscores the need for efficient and cost-effective treatments. The potential benefit of silymarin (extracted from the seeds of Silybum marianum or milk thistle) in the treatment of liver diseases remains a controversial issue. Therefore, the objective of this review is to assess the clinical efficacy and safety of silymarin by application of systematic approach. 525 references were found in the databases, of which 84 papers were retained for closer examination and 36 were deemed suitable for detailed analysis.

Silymarin has metabolic and cell-regulating effects at concentrations found in clinical conditions, namely carrier-mediated regulation of cell membrane permeability, inhibition of the 5-lipoxygenase pathway, scavenging of reactive oxygen species (ROS) of the R-OH type and action on DNA-expression, for example, via suppression of nuclear factor (NF)-κB.

Pooled data from case record studies involving 452 patients with Amanita phalloides poisoning show a highly significant difference in mortality in favour of silibinin [the main isomer contained in silymarin] (mortality 9.8% vs 18.3% with standard treatment; p < 0.01). The available trials in patients with toxic (e.g. solvents) or iatrogenic (e.g. antispychotic or tacrine) liver diseases, which are mostly outdated and underpowered, do not enable any valid conclusions to be drawn on the value of silymarin. The exception is an improved clinical tolerance of tacrine. In spite of some positive results in patients with acute viral hepatitis, no formally valid conclusion can be drawn regarding the value of silymarin in the treatment of these infections.

Although there were no clinical end-points in the four trials considered in patients with alcoholic liver disease, histological findings were reported as improved in two out of two trials, improvement of prothrombin time was significant (two trials pooled) and liver transaminase levels were consistently lower in the silymarin-treated groups. Therefore, silymarin may be of use as an adjuvant in the therapy of alcoholic liver disease. Analysis was performed on five trials with a total of 602 patients with liver cirrhosis. The evidence shows that, compared with placebo, silymarin produces a nonsignificant reduction of total mortality by −4.2% [odds ratio (OR) 0.75 (0.5–1.1)]; but that, on the other hand, the use of silymarin leads to a significant reduction in liver-related mortality of −7% [OR: 0.54 (0.3–0.9); p < 0.01]. An individual trial reported a reduction in the numberof patients with encephalopathy of −8.7% (p = 0.06). In one study of patients with cirrhosis-related diabetes mellitus, the insulin requirement was reduced by −25% (p < 0.01). We conclude that available evidence suggests that silymarin may play a role in the therapy of (alcoholic) liver cirrhosis.

Silymarin is has a good safety record and only rare case reports of gastrointestinal disturbances and allergic skin rashes have been published. This review does not aim to replace future prospective trials aiming to provide the ‘final’ evidence of the efficacy of silymarin.

References

  1. 1.
    Frömming KH, Saller R, Wächter W. Silymarinhaltige Phytopharmaka. Biopharmazie als wesentliches therapeutisches Qualitätskriterium. Z Arztl Fortbild Qualitätssich 1999; 93: 6–11Google Scholar
  2. 2.
    Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 1998; 3: 410–21PubMedGoogle Scholar
  3. 3.
    Michel H, Larrey D, Blanc P. Le traitement de l’hepatite alcoolique aigue. Ann Gastroenterol Hepatol Paris 1993; 29(1): 29–39PubMedGoogle Scholar
  4. 4.
    Luyckx F, Scheen AJ. Pharma-clinics. Le medicament du mois. Le Legalon (silymarine). Rev Med Liege 1997; 52: 792–6Google Scholar
  5. 5.
    Flora K, Hahn M, Rosen H, et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998; 93: 139–43PubMedCrossRefGoogle Scholar
  6. 6.
    Patrick L. Hepatitis C: epidemiology and review of complementary/alternative medicine treatments. Altern Med Rev 1999; 4: 220–38PubMedGoogle Scholar
  7. 7.
    World Health Organization: World Health Statistics Annual. Annex Table 3: Deaths by cause, sex and mortality stratum in WHO Regionsa, estimates for 1999. Table 4: Burden of disease in disability-adjusted life years (DALYs) by cause, sex and mortality stratum in WHO Regions, estimates for 1999 [online]. Available from URL: http://www.who.ch
  8. 8.
    Matthews GV, Nelson MR. The management of chronic hepatitis B infection. Int J STD AIDS 2001; 12: 353–7PubMedCrossRefGoogle Scholar
  9. 9.
    Foster GR, Caronia S. Pegylated interferons for hepatitis C CME in gastroenterology treatment updates. Medical Education Collaborative, Inc. and Medscape [online]. Available from URL: http://www.cochrane.co.uk [Accessed 2000]
  10. 10.
    Diehl AM. An update on nonalcoholic steatohepatitis Annual AGA Spring Postgraduate course, Session II: Liver. Program and abstracts of Digestive Disease Week; May 20–24, 2000; San Diego (CA)Google Scholar
  11. 11.
    Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347PubMedCrossRefGoogle Scholar
  12. 12.
    World Health Organization. Global surveillance and control of hepatitis C. J Viral Hep 1999; 6: 35–47CrossRefGoogle Scholar
  13. 13.
    Keeffe EB. Chapter VII Chronic hepatitis. In: Dale, DC, editor. Scientific American Medicine SAM-CD Connected. Copyright © 1999, Healtheon/WebMD, March 1999Google Scholar
  14. 14.
    Mulrow CD, Oxman AD, editors. Cochrane collaboration handbook [updated 9 December 1996]. The Cochrane Collaboration; Issue 1. Oxford: Update Software; 1997. Updated quarterly. Release date Jan 1997Google Scholar
  15. 15.
    Dobrilla G, Capurso L. Chapter 2. Meta-analisi: generalità. In: Dobrilla G Capurso L. Meta-Analisi in Gastroenterologia. Roma: II Pensiero Scientifico Editore, C 2000: 7–27Google Scholar
  16. 16.
    Software RevMan and RevMan manual. Version 3.0 Monica Fischer, NCC; Release date Oct 1996.Google Scholar
  17. 17.
    Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 1994; 27: 105–12PubMedGoogle Scholar
  18. 18.
    Invernizzi R, Bernuzzi S, Ciani D, et al. Silymarine during maintenance therapy of acute promyelocytic leukemia. Haematologica 1993; 78: 340–1PubMedGoogle Scholar
  19. 19.
    Lang I, Deak G, Nekam K, et al. Hepatoprotective and immunomodulatory effects of antioxidant therapy. Acta Med Hung 1988; 45: 287–95PubMedGoogle Scholar
  20. 20.
    Munter K, Mayer D. Faulstich H. Characterization of a transporting system in rat hepatocytes: studies with competitive and non-competitive inhibitors of phalloidin transport. Biochem Biophys Acta 1986; 860: 91–8Google Scholar
  21. 21.
    Faulstich H, Jahn W, Wieland T. Silybin inhibition of amatoxin uptake in the perfused rat liver. Arzneimittelforschung 1980; 30: 452–4PubMedGoogle Scholar
  22. 22.
    Hugentobler G, Kroncke KD, Fricker G, et al. Carrier mediated uptake of alpha amanitin in rat liver 18th Annual Meeting of the Union of Swiss Societies of Experimental Biology; Basel, Switzerland, 1986 Mar 20–21: Experientia Basel 1986; 42: 645Google Scholar
  23. 23.
    Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23: 749–54PubMedCrossRefGoogle Scholar
  24. 24.
    Lin AY, Rui YC. Inhibitory effect of silybin on the activity of 5-lipoxygenase of the porcine cerebral basilar artery. Chung Kuo Yao Li Hsueh Pao 1989; 10: 414–8PubMedGoogle Scholar
  25. 25.
    Dehmlow C, Murawski N, de Groot H. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 1996; 58: 1591–600PubMedCrossRefGoogle Scholar
  26. 26.
    Mira L, Silva M, Manso CF. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 1994; 48: 753–9PubMedCrossRefGoogle Scholar
  27. 27.
    El-Bahay C, Gerber E, Horbach M, et al. Influence of tumor necrosis factor-alpha and silibin on the cytotoxic action of alpha-amanitin in rat hepatocyte culture. Toxicol Appl Pharmacol 1999; 158: 253–60PubMedCrossRefGoogle Scholar
  28. 28.
    Miguez MP, Anundi I, Sainz-Pardo LA, et al. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem Biol Interact 1994; 91: 51–63PubMedCrossRefGoogle Scholar
  29. 29.
    Feher J, Lang I, Nekam K, et al. Effect of free radical scavengers on Superoxide dismutase (SOD) enzyme in patients with alcoholic cirrhosis. Acta Med Hung 1988; 45: 265–76PubMedGoogle Scholar
  30. 30.
    Saliou C, Rihn B, Cillard J, et al. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. FEBS Lett 1998; 440: 8–12Google Scholar
  31. 31.
    Saliou C, Kitazawa M, McLaughlin L, et al. Antioxidants modulate acute solar ultraviolet radiation-induced NF-kappa-B activation in a human keratinocyte cell line. Free Radic Biol Med 1999; 26: 174–83PubMedCrossRefGoogle Scholar
  32. 32.
    Harakeh S, Jariwalla RJ. NF-kappa B-independent suppression of HIV expression by ascorbic acid. AIDS Res Hum Retro-viruses 1997; 13: 235–9CrossRefGoogle Scholar
  33. 33.
    Manna SK, Mukhopadhyay A, Van NT, et al. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol 1999; 163: 6800–9PubMedGoogle Scholar
  34. 34.
    Favari L, Perez-Alvarez V. Comparative effects of colchicine and silymarin on CC14-chronic liver damage in rats. Arch Med Res 1997; 28: 11–7PubMedGoogle Scholar
  35. 35.
    Mourelle M, Muriel P, Favari L, et al. Prevention of CCL4-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 1989; 3: 183–91PubMedCrossRefGoogle Scholar
  36. 36.
    Boigk G, Stroedter L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997; 26: 643–9PubMedCrossRefGoogle Scholar
  37. 37.
    Deak G, Muzes G, Lang I, et al. Effects of two bioflavonoids on certain cellular immune reactions in vitro. Acta Physiol Hung 1990; 76: 113–21PubMedGoogle Scholar
  38. 38.
    Wenzel S, Stolte H, Soose M. Effects of silibinin and antioxidants on high glucose-induced alterations of fibronectin turnover in human mesangial cell cultures. J Pharmacol Exp Ther 1996; 279: 1520–6PubMedGoogle Scholar
  39. 39.
    Neuman MG, Cameron RG, Haber JA, et al. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity. Clin Biochem 1999; 32: 519–36PubMedCrossRefGoogle Scholar
  40. 40.
    von Schonfeld J, Weisbrod B, Muller MK. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cell Mol Life Sci 1997; 53: 917–20CrossRefGoogle Scholar
  41. 41.
    Gorio A, Donadoni ML, Finco C, et al. Endogenous mono-ADP-ribosylation in retina and peripheral nervous system. Effects of diabetes. Adv Exp Med Biol 1997; 419: 289–95Google Scholar
  42. 42.
    Soto CP, Perez BL, Favari LP, et al. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998; 119: 125–9PubMedCrossRefGoogle Scholar
  43. 43.
    Leng-Peschlow E, Strenge-Hesse A. Die Mariendistel (Silybum marianum) und Silymarin als Lebertherapeutikum. Zeitschr für Phytother 1991; 12: 162–74Google Scholar
  44. 44.
    Chasseaud LF. (Huntingdon Research Centre, unpublished data; cf. Mennicke W.II (1975)): Zur biologischen Verfügbarkeit und Verstoffwechselung von Silybin. Dtsch Apoth Ztg 115: 1205–6Google Scholar
  45. 45.
    Koch H, Zinsberger G. Löslichkeitsparameter von Silybin, Silydianin und Silychristin. Arch Pharm 1980; 313: 526–33CrossRefGoogle Scholar
  46. 46.
    Eder M, Mehnert W. Bedeutung pflanzlicher Begleitstoffe in Extrakten. Pharmazie 1998; 53: 285–93PubMedGoogle Scholar
  47. 47.
    Morazzoni P, Magistretti MJ, Giachetti C, et al. Comparative bioavailability of Silipide, a new flavanolignan complex, in rats. Eur J Drug Metab Pharmacokinet 1992; 1: 39–44CrossRefGoogle Scholar
  48. 48.
    Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on IdB 1016, a sylibin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990; 15: 333–8PubMedCrossRefGoogle Scholar
  49. 49.
    Savio D, Harrasser PC, Basso G. Softgel capsule technology as an enhancer device for the absorption of natural principles in humans. Arzneim Forsch Drug Res 1998; 48(II): 1104–6Google Scholar
  50. 50.
    Arcari M, Brambilla A, Brandt A, et al. Nuovo complesso di inclusione tra silibina e la β-cyclodestrina: velocita di dissoluzione in vitro in confronto a formulazioni tradizionali. Boll Chim Farm 1992; 131: 205–9PubMedGoogle Scholar
  51. 51.
    Schulz H-U, Schürer M, Krumbiegel G, et al. Untersuchungen zum Freisetzungsverhalten und zur Bioäquivalenz von Silymarin-Präparaten. Arzneim Forsch Drug Res 1995; 45(I): 61–4Google Scholar
  52. 52.
    Gatti G, Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidyl complex (silipide) in healthy volunteers. Int J Clin Pharmacol Ther 1994; Nov 32: 614–7PubMedGoogle Scholar
  53. 53.
    Weyhenmeyer R, Mascher H, Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Intl J Clin Pharmacol Ther 1992; 30: 134–8Google Scholar
  54. 54.
    Lorenz D, Lücker PW, Mennicke WH, et al. Pharmacokinetic Studies with silymarin in human serum and bile meth and find. Exptl Clin Pharmacol 1984; 6: 655–61Google Scholar
  55. 55.
    Flory PJ, Krag G, Lorenz D, et al. Untersuchungen zur Elimination von Silymarin bei cholezystektomierten Patienten. 1. Mitteilung: Biliäre und renale Elimination nach einmaliger oraler Gabe. Planta Med 1980; 38: 227Google Scholar
  56. 56.
    Lorenz D, Mennicke WH, Behrendt W. Untersuchungen zur Elimination von Silymarin bei cholezystektomieren Patienten. 2. Mitteilung: Biliäre Elimination nach mehrfacher oraler Gabe. Planta Med 1982; 45: 216–23Google Scholar
  57. 57.
    Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung 1992; 42: 964–8PubMedGoogle Scholar
  58. 58.
    Varga M, Buris L, Fodor M. Ethanol elimination in man under influence of hepatoprotective silibinin. Blutalkohol 1991; 28: 405–8PubMedGoogle Scholar
  59. 59.
    Orlando R, Fragasso A, Lampertico M, et al. Silybin kinetics in patients with liver cirrhosis: comparative study between silybin-phosphatidylcholine complex and silymarin. Med Sci Res 1990; 18: 861–3Google Scholar
  60. 60.
    Orlando R, Fragasso A, Lampertico M, et al. Pharmacokinetic study of silybin-phosphatidylcholin complex in liver cirrhosis after multiple doses. Med Sci Res 1990; 19: 827–8Google Scholar
  61. 61.
    Olson KR, Patel MM. Chapter II Food poisoning in Scientific American Medicine. SAM-CD Connected, January 1994Google Scholar
  62. 62.
    Floersheim GL. Treatment of mushroom poisoning [letter]. JAMA 1985; 253: 3252CrossRefGoogle Scholar
  63. 63.
    Parish RC, Doering PL. Treatment of Amanita mushroom poisoning: a review. Vet Hum Toxicol 1986; 28: 318–22PubMedGoogle Scholar
  64. 64.
    Hruby K, Csomos G, Fuhrmann M, et al. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol 1983; 2: 183–95PubMedCrossRefGoogle Scholar
  65. 65.
    Tuchweber B, Sieck R, Trost W. Prevention of silybin of phalloidin-induced acute hepatoxicity. Toxicol Appl Pharmacol 1979; 51: 265–75PubMedCrossRefGoogle Scholar
  66. 66.
    Piqueras Carrasco J. Intoxicacion por setas tipo Amanita phalloides. Med Clin (Barc) 1985; 85: 330–40Google Scholar
  67. 67.
    Richter M, Simmen R, Severe Vomiting, diarrhea (Clinical Conference) Schweiz Rundsch Med Prax 1990, 79: 1031–3Google Scholar
  68. 68.
    Vesconi. Quoted in: Parish RC, Doering PL. Treatment of Amanita mushroom poisoning: areview. Vet Hum Toxicol 1986; 28: 318–22Google Scholar
  69. 69.
    Strenge-Hesse A. Unpublished report on spontaneously reported cases in Germany, by Madaus AG, Cologne, Germany, 1996. Data on fileGoogle Scholar
  70. 70.
    Allain H, Schuck S, Lebreton S, et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 1999; 10: 181–5PubMedCrossRefGoogle Scholar
  71. 71.
    Fintelmann V. Postoperatives Verhalten der Serumcholine-sterase und anderer Leberenzyme. Med Klin 1973; 68: 809–15PubMedGoogle Scholar
  72. 72.
    Lahtinen J, Hendolin H, Tuppurainen T. Die Wirkung von Silymarin auf Leberfunktionstests nach Cholezystektomie unter Allgemeinanästhesie. De Ritis F, Csomos G, Braatz R. Der toxisch-metabolische Leberschaden. Lübeck: Hansisches Verlagskontor 1981; 79–82Google Scholar
  73. 73.
    Saba P, Galeone F, Salvadorini F, et al. Therapeutic action of Silymarin on chronic hepatopathies caused by psychopharmaceuticals. Gazz Med Ital 1976; 135: 236–51Google Scholar
  74. 74.
    Boari C, Montanari FM, Galletti GP, et al. Epatopatie tossiche professionali. Effetti terapeutici della silimarina. Minerva Med 1981; 72: 2679–88Google Scholar
  75. 75.
    Szilard S, Szentgyorgyi D, Demeter I. Protective effect of Legalon in workers exposed to organic solvents. In: Acta Med Hung 1988; 45: 249–56Google Scholar
  76. 76.
    Palasciano G, Portincasa P, Palmieri V, et al. The effect of silymarin on plasma levels of malon-dialdehyde in patients receinving longterm treatment with psychotropic Drugs. Curr Ther Res 1994: 5: 537–45CrossRefGoogle Scholar
  77. 77.
    Keeffe EB. Chapter VII Acute hepatitis. In: Dale DC, editor. Scientific American Medicine SAM-CD Connected. Copyright © 1999, Healtheon/WebMD, March 1999Google Scholar
  78. 78.
    Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422–7PubMedCrossRefGoogle Scholar
  79. 79.
    Bonis PA, Friedman L, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001; 344(6): 452–4PubMedCrossRefGoogle Scholar
  80. 80.
    Rosen HR, Gretch DR. Hepatitis C virus: current understanding and prospects for future therapies. Mol Med Today 1999; 5: 393–9PubMedCrossRefGoogle Scholar
  81. 81.
    Kiesewetter E, Leodolter I, Thaler H. Ergebnisse zweier Doppelblindstudien zur Wirksamkeit von Silymarin bei chronischer Hepatitis. Leber Magen Darm 1977; 7: 318–23PubMedGoogle Scholar
  82. 82.
    Bode JC, Schmidt U, Durr HK. Zur Behandlung der akuten Virushepatitis mit Silymarin. Ergebnisse einer kontrollierten Studie. Med Klin 1977; 72: 513–8Google Scholar
  83. 83.
    Magliulo E, Gagliardi B, Fiori GP. Zur Wirkung von Silymarin bei der Behandlung der akuten Virushepatitis. Ergebnis einer an zwei medizinischen Zentren durchgefuhrten Doppelblindstudie. Med Klin 1978; 73: 1060–5Google Scholar
  84. 84.
    Musso A, Giacchino M, Vietti M, et al. Considerazioni sull’uso della Silimarina e della SAMe nel trattamento dell’epatite infettiva acuta dell’infanzia. Minerva Pediatr 1980; 32: 1057–67PubMedGoogle Scholar
  85. 85.
    Lirussi F, Okolicsanyi L. Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease. Acta Physiol Hung 1992; 80: 363–7PubMedGoogle Scholar
  86. 86.
    Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 1993; 31: 456–60PubMedGoogle Scholar
  87. 87.
    Mantle D, Preedy VR. Free radicals as mediators of alcohol toxicity. Adverse Drug React Toxicol Rev 1999; 18: 235–52PubMedGoogle Scholar
  88. 88.
    Apte MV, Phillips PA, Fahmy RG, et al. Does alcohol directly stimulate pancreatic fibrogenesis? Studies with rat pancreatic stellate cells. Gastroenterology 2000; 118: 780–94PubMedCrossRefGoogle Scholar
  89. 89.
    Muzes G, Deak G, Lang I, et al. Silymarin (Legalon) kezeles hatasa idult alkoholos majbetegek antioxidans vedorends-zerere es a lipid peroxidaciora (kettos vak protokoll). Orv Hetil 1990; 131: 863–6PubMedGoogle Scholar
  90. 90.
    Fintelmann V, Albert A. Nachweis der therapeutischen Wirksamkeit von Legalon bei toxischen Lebererkrankungen im Doppelblindversuch. Therapiewoche 1980; 30: 5589–94Google Scholar
  91. 91.
    Di Mario F, Farini R, Okolicsanyi L, et al. Die Wirkung von Legalon auf die Leberfunktionsproben bei Patienten mit alkoholbedingter Lebererkrankung, Doppelblindstudie. In: De Ritis F, Csomos G, Braatz R. Der toxisch-metabolische Leberschaden. Lübeck: Hansisches Verlagskontor, 1981; 54–8Google Scholar
  92. 92.
    Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 1982; 17: 517–21Google Scholar
  93. 93.
    Feher J, Deak G, Muzes G, et al. Silymarin kezeles majvedo hatasa idult alkoholos majbetegsegben. Orv Hetil 1989; 130: 2723–7PubMedGoogle Scholar
  94. 94.
    Giannini E, Caglieris S, Ceppa P, et al. Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2001 Feb; 13: 137–41PubMedCrossRefGoogle Scholar
  95. 95.
    Albrecht M, Frerick H, Kuhn U, et al. Die Therapie toxischer Leberschäden mit Legalon. Z Klein Med 1992; 47: 87–92Google Scholar
  96. 96.
    Grüngreiff K, Albrecht M, Stregen-Hesse A. Nutzen der medikamentösen Lebertherapie in der hausärztlichen Praxis. Medwelt 1995; 46: 222–7Google Scholar
  97. 97.
    Lok A. Current treatment options in chronic hepatitis B Annual AGA Spring Postgraduate Course, Session II: Liver. Program and abstracts of Digestive Disease Week 2000 May 20–24; San Diego (CA)Google Scholar
  98. 98.
    Linhart HG. Non-alcoholic steato-hepatitis. Schweiz Rundsch Med Prax 2000 May 31; 89: 963–6Google Scholar
  99. 99.
    Oellerich M, Burdelski M, Lautz H, et al. Prediction of one-year pretransplant survival in patients with cirrhosis. Hepatology 1991; 14: 1029PubMedCrossRefGoogle Scholar
  100. 100.
    Runyon B. Care of patients with ascites. N Engl J Med 1994; 330: 337PubMedCrossRefGoogle Scholar
  101. 101.
    Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105–13PubMedCrossRefGoogle Scholar
  102. 102.
    Trinchet JC, Coste T, Levy VG, et al. Traitement de l’hepatite alcoolique par la silymarine. Une etude comparative en double insu chez 116 malades. Gastroenterol Clin Biol 1989; 13: 120–4Google Scholar
  103. 103.
    Bunout D, Hirsch S, Petermann M, et al. Estudio controlado sobre el efecto de la silimarina en la enfermedad hepatica alcoholica. Rev Med Chil 1992; 120: 1370–5PubMedGoogle Scholar
  104. 104.
    Velussi M, Cernigoi AM, De Monte A, et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997; 26(4): 871–9PubMedCrossRefGoogle Scholar
  105. 105.
    Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial [see comments]. J Hepatol 1998; 28: 615–21PubMedCrossRefGoogle Scholar
  106. 106.
    Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513–20PubMedCrossRefGoogle Scholar
  107. 107.
    Lebrec D, De Fleury P, Rueff B, et al. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 1980; 79: 1139PubMedGoogle Scholar
  108. 108.
    Petrides AS, Vogt C, Schulze-Berge D, et al. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616–27PubMedCrossRefGoogle Scholar
  109. 109.
    Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059–63PubMedCrossRefGoogle Scholar
  110. 110.
    An adverse reaction to the herbal medication milk thistle (Silybum marianum). Adverse Drug Reactions Advisory Committee. Med J Aust 1999; 170: 218–9Google Scholar
  111. 111.
    CIOMS Report 1980–1996. Madaus GmbH. Cologne, Germany. Data on file.Google Scholar
  112. 112.
    Spontaneously reported adverse events (AEs) in the screened literature and recorded by the originator of silymarin for the period 1980 to 1996. Madaus. Data on file.Google Scholar
  113. 113.
    Walti M, Neftel KA, Jost R, et al. IgE-und IgG-Antikorper gegen Flavonoide nach Therapie mit flavonoidhaltigen Medikamenten. Schweiz Med Wochenschr 1986; 116(4): 98–103PubMedGoogle Scholar
  114. 114.
    Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000; 86: 250–6PubMedCrossRefGoogle Scholar
  115. 115.
    Madaus AG. Legalon (silymarin) user information. Koln, Germany, 2001Google Scholar
  116. 116.
    Pepping J. Milk thistle: Silybum marianum. Am J Health Syst Pharm 1999; 56: 1195–7PubMedGoogle Scholar
  117. 117.
    Dobrilla G, Capurso L. Chapter 14. Epatite croniche. In: Dobrilla G, Capurso L. Meta-Analisi in Gastroenterologia. Roma: II Pensiero Scientifico Editore, 2000: 171Google Scholar
  118. 118.
    Perrier A. Evidence-based medicine and critical care. Schweiz Med Wochenschr 1999; 129: 1572–82PubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Reinhard Saller
    • 1
  • Remy Meier
    • 2
  • Reto Brignoli
    • 3
  1. 1.Abteilung Naturheilkunde, Departement für Innere MedizinUniversity Hospital ZurichZurichSwitzerland
  2. 2.Department of GastroenterologyUniversity of BaselLiestalSwitzerland
  3. 3.Tradyser GmbHRueschlikonSwitzerland

Personalised recommendations